fig5
Figure 5. Structures of CDK inhibitors and the IGF-1R inhibitor linsitinib with effects on MYB activity and/or MYB-dependent cancers (green: mechanisms; red: targeted cancers). CDK: Cyclin-dependent kinase; IGF-1R: insulin-like growth factor 1 receptor.
